(Gly¹⁴)-Humanin (human) |
Catalog No.GA20196
One-Click Copy Product Info
|
(Gly14)-Humanin (human) is a potent analogue of Humanin, with highly neuroprotective activity.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 330936-70-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
(Gly14)-Humanin (human) is a potent analogue of Humanin, with highly neuroprotective activity[1]. (Gly14)-Humanin activates the Nrf2/GPX4 pathway, which reduces cellular oxidative stress and inhibits ferroptosis, thereby alleviating oligoasthenozoospermia in mice[2]. (Gly14)-Humanin has been widely used in vascular endothelial research to prevent lipid aggregation and cell death[3].
In vitro, (Gly14)-Humanin (0.1µM) was pre-treated for 6 hours, which protected PC12 cells from cell death induced by Aβ25-35, restored mitochondrial membrane potential and blocked the release of cytochrome c[4]. 1µM of (Gly14)-Humanin pretreatment for 3 hours inhibited apoptosis in human umbilical vein endothelial cells (HUVECs) triggered by high glucose (50mM) and reduced ROS production and PARP expression[5].
In vivo, (Gly14)-Humanin treatment via a single injection (i.c.v.) at a dose of 1000pmol (5µl) within 30 minutes improved scopolamine-caused learning and memory deficits in mice[6]. Continuous intraperitoneal injection of (Gly14)-Humanin (10mg/kg/day) for 6 consecutive weeks improved ovarian function and body weight in a mouse model of primary ovarian insufficiency and alleviated ovarian oxidative stress[7]. (Gly14)-Humanin (0.1µg) was administered (i.p.) every other day for 3 months, which improved the cognitive deficits in the middle-aged APPswe/PS1dE9 mice and reduced Aβ plaque deposition and alleviated neuroinflammation[8].
References:
[1] Wang T, Zhang L, Zhang M, et al. [Gly14]-Humanin reduces histopathology and improves functional outcome after traumatic brain injury in mice[J]. Neuroscience, 2013, 231: 70-81.
[2] Liu Y, Feng Q, Zou L, et al. Oligoasthenozoospermia is alleviated in a mouse model by [Gly14]‐humanin‐mediated attenuation of oxidative stress and ferroptosis[J]. Andrology, 2025, 13(6): 1541-1555.
[3] Ding Y, Feng Y, Zhu W, et al. [Gly14]‐Humanin Prevents Lipid Deposition and Endothelial Cell Apoptosis in a Lectin‐like Oxidized Low‐density Lipoprotein Receptor‐1‐Dependent Manner[J]. Lipids, 2019, 54(11-12): 697-705.
[4] Jin H, Liu T, Wang W X, et al. Protective effects of [Gly14]-Humanin on β-amyloid-induced PC12 cell death by preventing mitochondrial dysfunction[J]. Neurochemistry international, 2010, 56(3): 417-423.
[5] Xie Y, Liu Z, Li X, et al. Protection effect of [Gly14]-Humanin from apoptosis induced by high glucose in human umbilical vein endothelial cells[J]. Diabetes research and clinical practice, 2014, 106(3): 560-566.
[6] Mamiya T, Ukai M. [Gly14]‐Humanin improved the learning and memory impairment induced by scopolamine in vivo[J]. British journal of pharmacology, 2001, 134(8): 1597-1599.
[7] Huang J, Feng Q, Zou L, et al. [Gly14]-humanin exerts a protective effect against D-galactose-induced primary ovarian insufficiency in mice[J]. Reproductive BioMedicine Online, 2024, 48(2): 103330.
[8] Zhang W, Zhang W, Li Z, et al. S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice[J]. Pharmacology Biochemistry and Behavior, 2012, 100(3): 361-369.
| Cell experiment [1]: | |
|
Cell lines |
Human umbilical vein endothelial cells (HUVECs) |
|
Preparation Method |
HUVECs were cultured in DMEM medium, supplemented with 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin at 37°C in an incubator with 5% CO2. High glucose treatment was performed by treating HUVECs with 30mM glucose for 72h. Controls were performed in the presence of media with normal glucose alone (5.5mM). Cells were pretreated with (Gly14)-Humanin (1µM; 3h) before exposure to high glucose. Collect cells and analyze the levels of β-galactosidase and SIRT6. |
|
Reaction Conditions |
1µM; 3h |
|
Applications |
(Gly14)-Humanin pretreatment inhibited high-glucose induced β-galactosidase upregulation and SIRT6 downregulation in HUVECs. |
| Animal experiment [2]: | |
|
Animal models |
Female APPswe/PS1dE9 mice |
|
Preparation Method |
Female APPswe/PS1dE9 mice were housed under standard conditions: temperature (22-24°C) and humidity (40-60%), 12h light/dark cycle with ad libitum access to food and normal drinking water. Each mouse with (Gly14)-Humanin treatment received (Gly14)-Humanin dissolved in normal saline every other day by intraperitoneal injection (0.1μg/0.5ml in saline), while each mouse with vehicle treatment received an equal volume of saline injection (0.5ml) as the control. Treatment was started when the mice were 9 months old and was continued for 3 months. Mice were deeply anesthetized with sodium pentobarbital (100mg/kg; i.p.), and perfused transcardially with 100ml of cold normal saline. Brains were removed for analysis. |
|
Dosage form |
0.1µg; every other day; 3 months; i.p. |
|
Applications |
(Gly14)-Humanin significantly reduced cerebral Aβ plaque deposition, insoluble Aβ levels, and neuroinflammatory responses in APPswe/PS1dE9 mice. |
References: [1] Li M, Liu Z, Cao X, et al. [Gly14]-Humanin ameliorates high glucose-induced endothelial senescence via SIRT6[J]. Scientific Reports, 2024, 14(1): 30924. [2] Zhang W, Zhang W, Li Z, et al. S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice[J]. Pharmacology Biochemistry and Behavior, 2012, 100(3): 361-369. | |
| Cas No. | 330936-70-4 | SDF | |
| Formula | C118H202N34O31S2 | M.Wt | 2657.25 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 376.3 μL | 1.8816 mL | 3.7633 mL |
| 5 mM | 75.3 μL | 376.3 μL | 752.7 μL |
| 10 mM | 37.6 μL | 188.2 μL | 376.3 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)